NasdaqGS - Nasdaq Real Time Price USD

Nanobiotix S.A. (NBTX)

4.6759
-0.0341
(-0.72%)
As of 2:02:42 PM EDT. Market Open.
Loading Chart for NBTX
  • Previous Close 4.7100
  • Open 4.8499
  • Bid --
  • Ask --
  • Day's Range 4.6759 - 4.8499
  • 52 Week Range 2.7600 - 6.0000
  • Volume 1,223
  • Avg. Volume 11,147
  • Market Cap (intraday) 221.66M
  • Beta (5Y Monthly) 1.56
  • PE Ratio (TTM) --
  • EPS (TTM) -1.6400
  • Earnings Date May 21, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 7.45

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.

www.nanobiotix.com

108

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NBTX

View more

Performance Overview: NBTX

Trailing total returns as of 6/9/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

NBTX
56.38%
CAC 40 (^FCHI)
5.56%

1-Year Return

NBTX
17.97%
CAC 40 (^FCHI)
2.63%

3-Year Return

NBTX
0.56%
CAC 40 (^FCHI)
22.54%

5-Year Return

NBTX
74.24%
CAC 40 (^FCHI)
52.92%

Compare to: NBTX

Select to analyse similar companies using key performance metrics; select up to four stocks.

Statistics: NBTX

View more

Valuation Measures

Annual
As of 4/7/2025
  • Market Cap

    225.58M

  • Enterprise Value

    226.91M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.43

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    3.39

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -52.89%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    -7.19M

  • Net Income Avi to Common (ttm)

    -68.13M

  • Diluted EPS (ttm)

    -1.6400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    49.74M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -33.16M

Research Analysis: NBTX

View more

Company Insights: NBTX

Research reports: NBTX

View more

People Also Watch